Waverley Pharma Inc.
WAVE.V
TSX
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -15.73% | 1,873.17% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -15.73% | 1,873.17% | |||
| Cost of Revenue | -4.20% | 3,077.19% | |||
| Gross Profit | -30.46% | 1,231.78% | |||
| SG&A Expenses | -44.15% | 281.10% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -27.92% | 115.52% | |||
| Operating Income | 81.39% | 56.14% | |||
| Income Before Tax | 46.14% | 76.71% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 46.14% | 76.71% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 46.14% | 76.71% | |||
| EBIT | 81.39% | 56.14% | |||
| EBITDA | 101.88% | 61.74% | |||
| EPS Basic | 44.44% | 75.68% | |||
| Normalized Basic EPS | 40.00% | 78.26% | |||
| EPS Diluted | 44.44% | 87.67% | |||
| Normalized Diluted EPS | 40.00% | 78.26% | |||
| Average Basic Shares Outstanding | 0.00% | 0.00% | |||
| Average Diluted Shares Outstanding | 0.00% | 0.00% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||